[HTML][HTML] Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber, K Fleetwood… - Multiple sclerosis and …, 2019 - Elsevier
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
R McCool, K Wilson, M Arber, K Fleetwood… - Multiple Sclerosis and …, 2019 - europepmc.org
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
[引用][C] Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber, K Fleetwood… - Multiple Sclerosis and …, 2019 - cir.nii.ac.jp
Systematic review and network meta-analysis comparing ocrelizumab with other treatments
for relapsing multiple sclerosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
for relapsing multiple sclerosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber… - Multiple …, 2019 - research-information.bris.ac.uk
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
[HTML][HTML] Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber… - Multiple Sclerosis …, 2019 - msard-journal.com
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber… - Multiple sclerosis …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …